Late catch from 15 October: Recursion announced a $200 million underwritten follow-on offering, updated human data for REC-4881 and the RBM39 degrader REC-1245, and Sanofi’s option of the first development candidate from their collaboration….
Sanofi and Regeneron expanded their immunology alliance around four long-acting antibodies spanning IL-13, IL-4×IL-13, IL-4 and IL-4Rα. Sanofi will pay Regeneron $1 billion upfront; up to $7 billion more is contingent on development, regulatory…
Sanofi discontinued the clinical programs for itepekimab and balinatunfib as part of a wider pipeline prioritization. Itepekimab will stop across COPD and chronic rhinosinusitis after review of two Phase 3 COPD studies and the…
Scribe Therapeutics priced an upsized initial public offering of 8.58 million shares at $15, raising $128.7 million gross before expenses and the underwriters’ option. Trading is expected to begin July 24 under SCTX, with…
Sanofi discontinued development of amlitelimab in moderate-to-severe atopic dermatitis and will not seek global approval after concluding that the totality of efficacy and safety did not support further development. The decision is strategically important…
The FDA approved subcutaneous Sarclisa (isatuximab-irfc) Escena across all existing Sarclisa IV indications in multiple myeloma. It is the first anticancer treatment administered via an on-body injector, and the first myeloma therapy available by…
